NO20001555D0 - Azabenzimidazolbaserte forbindelser for modulering av serin/treonin proteinkinasefunksjon - Google Patents

Azabenzimidazolbaserte forbindelser for modulering av serin/treonin proteinkinasefunksjon

Info

Publication number
NO20001555D0
NO20001555D0 NO20001555A NO20001555A NO20001555D0 NO 20001555 D0 NO20001555 D0 NO 20001555D0 NO 20001555 A NO20001555 A NO 20001555A NO 20001555 A NO20001555 A NO 20001555A NO 20001555 D0 NO20001555 D0 NO 20001555D0
Authority
NO
Norway
Prior art keywords
threonine protein
azabenzimidazole
protein kinase
serine
based compounds
Prior art date
Application number
NO20001555A
Other languages
English (en)
Other versions
NO325663B1 (no
NO20001555L (no
Inventor
Gerald Mcmahon
Heinz Weinberger
Bernard Kutscher
Harald App
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of NO20001555L publication Critical patent/NO20001555L/no
Publication of NO20001555D0 publication Critical patent/NO20001555D0/no
Publication of NO325663B1 publication Critical patent/NO325663B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20001555A 1997-09-26 2000-03-24 Azabenzimidazolbaserte forbindelser, fremgangsmater for fremstilling av forbindelsene, anvendelse av forbindelsene samt farmasoytiske sammensetninger inneholdende forbindelsene NO325663B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6014597P 1997-09-26 1997-09-26
PCT/US1998/019973 WO1999016438A1 (en) 1997-09-26 1998-09-23 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function

Publications (3)

Publication Number Publication Date
NO20001555L NO20001555L (no) 2000-03-24
NO20001555D0 true NO20001555D0 (no) 2000-03-24
NO325663B1 NO325663B1 (no) 2008-07-07

Family

ID=22027657

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001555A NO325663B1 (no) 1997-09-26 2000-03-24 Azabenzimidazolbaserte forbindelser, fremgangsmater for fremstilling av forbindelsene, anvendelse av forbindelsene samt farmasoytiske sammensetninger inneholdende forbindelsene

Country Status (28)

Country Link
US (2) US6093728A (no)
EP (1) EP1017384B1 (no)
JP (1) JP2001517699A (no)
KR (1) KR100547929B1 (no)
CN (1) CN1167420C (no)
AR (1) AR017266A1 (no)
AT (1) ATE281834T1 (no)
AU (1) AU748849B2 (no)
BG (1) BG64784B1 (no)
BR (1) BR9812682A (no)
CA (1) CA2305370C (no)
DE (1) DE69827516T2 (no)
DK (1) DK1017384T3 (no)
ES (1) ES2230719T3 (no)
HK (1) HK1032206A1 (no)
HU (1) HUP0004024A3 (no)
IL (4) IL135109A0 (no)
NO (1) NO325663B1 (no)
NZ (2) NZ503432A (no)
PL (1) PL191618B1 (no)
PT (1) PT1017384E (no)
RU (1) RU2230553C2 (no)
SK (1) SK285357B6 (no)
TR (1) TR200001546T2 (no)
TW (1) TW581815B (no)
UA (1) UA72448C2 (no)
WO (1) WO1999016438A1 (no)
ZA (1) ZA988797B (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060142236A1 (en) * 1994-05-31 2006-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6384049B1 (en) * 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment
WO2002072090A1 (en) * 2001-03-12 2002-09-19 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2005013950A2 (en) * 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
EP1962892A4 (en) 2005-11-22 2011-10-12 Univ South Florida INHIBITION OF CELL PROLIFERATION
US7951819B2 (en) 2006-04-26 2011-05-31 Cancer Research Technology Limited Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
ZA200902382B (en) 2006-10-19 2010-08-25 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
EP2839839B1 (en) * 2007-02-28 2018-01-17 Yeda Research And Development Company Limited Nuclear targeting sequences
CA2689514C (en) 2007-06-05 2015-09-29 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JP5350247B2 (ja) * 2007-08-29 2013-11-27 武田薬品工業株式会社 複素環化合物およびその用途
NZ586418A (en) 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
GB0807609D0 (en) 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2010025448A2 (en) * 2008-08-29 2010-03-04 University Of South Florida Inhibition of cell proliferation
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
WO2010064611A1 (ja) 2008-12-01 2010-06-10 武田薬品工業株式会社 複素環化合物およびその用途
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
JP2012197231A (ja) * 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
JP2013508456A (ja) 2009-10-26 2013-03-07 シグナル ファーマシューティカルズ， エルエルシー ヘテロアリール化合物の合成方法および精製方法
WO2011092469A1 (en) 2010-02-01 2011-08-04 Cancer Research Technology Limited 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
EP3659599B1 (en) 2011-10-19 2022-12-21 Signal Pharmaceuticals, LLC 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one for use in the treatment of glioblastoma multiforme
CA3125862A1 (en) 2011-12-02 2013-06-06 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
US9375443B2 (en) 2012-02-24 2016-06-28 Signal Pharmaceuticals, Llc Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinib
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
ES2638179T3 (es) 2013-01-16 2017-10-19 Signal Pharmaceuticals, Llc Compuestos de pirrolopirimidina sustituidos, composiciones de los mismos, y métodos de tratamiento con los mismos
ES2885424T3 (es) 2013-03-15 2021-12-13 Knopp Biosciences Llc Imidazo(4,5-B)piridin-2-il amidas como activadores del canal Kv7
CN105392499B (zh) 2013-04-17 2018-07-24 西格诺药品有限公司 用于治疗癌症的包含tor激酶抑制剂和胞苷类似物的组合疗法
TW201521725A (zh) 2013-04-17 2015-06-16 Signal Pharm Llc 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
AU2014254058B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a Dihydropyrazino-Pyrazine Compound and an androgen receptor antagonist for treating prostate cancer
US9474757B2 (en) 2013-04-17 2016-10-25 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
KR102221029B1 (ko) 2013-04-17 2021-02-26 시그날 파마소티칼 엘엘씨 디하이드로피라지노-피라진을 사용한 암의 치료
UA119538C2 (uk) 2013-04-17 2019-07-10 Сігнал Фармасьютікалз, Елелсі Лікування злоякісної пухлини дигідропіразинопіразинами
KR102459285B1 (ko) 2013-04-17 2022-10-27 시그날 파마소티칼 엘엘씨 1-에틸-7-(2-메틸-6-(1H-1,2,4-트리아졸-3-일)피리딘-3-일)-3,4-디하이드로피라지노[2,3-b]피라진-2(1H)-온에 관한 약학 제제, 제조방법, 고체 형태 및 사용 방법
CN107474051B (zh) 2013-05-29 2020-10-30 西格诺药品有限公司 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
WO2015040609A1 (en) 2013-09-17 2015-03-26 Yeda Research And Development Co. Ltd. Erk-derived peptides and uses thereof
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
JP2017514806A (ja) 2014-04-16 2017-06-08 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
KR20170024120A (ko) 2014-07-14 2017-03-06 시그날 파마소티칼 엘엘씨 치환된 피롤로피리미딘 화합물을 사용한 암의 치료방법, 이의 조성물
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
US9481653B2 (en) 2014-09-12 2016-11-01 Knopp Biosciences Llc Benzoimidazol-1,2-yl amides as Kv7 channel activators
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3590045A (en) * 1969-09-25 1971-06-29 Smith Kline French Lab Certain substituted imidazo (4,5-b)pyridines
BE788065A (fr) 1971-08-26 1973-02-26 Degussa Nouvelles aza-benzimidazoles et procede pour leur preparation
SE422799B (sv) 1975-05-28 1982-03-29 Merck & Co Inc Analogiforfarande for framstellning av 1,3-dihydroimidazo (4,5-b)pyridin-2-oner
ES473201A1 (es) * 1977-09-26 1979-03-16 Degussa Procedimiento para la preparacion de 7-azabencimidazoles
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
US5326905A (en) * 1990-04-02 1994-07-05 Pfizer Inc. Benzylphosphonic acid tyrosine kinase inhibitors
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5409930A (en) * 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6194439B1 (en) * 1991-05-29 2001-02-27 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
RU2155187C2 (ru) * 1992-08-06 2000-08-27 Варнер-Ламберт Компани Производные индола, их таутомеры, смеси их изомеров или отдельные изомеры и фармацевтически приемлемые соли, фармацевтическая композиция с антиопухолевой или ингибирующей протеин-тирозинкиназу активностью и способ торможения зависящего от протеин-тирозинкиназы заболевания или борьбы с аберрантным ростом клеток млекопитающего или человека.
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5582995A (en) 1993-06-11 1996-12-10 The General Hospital Corporation Methods of screening for compounds which inhibit the direct binding of Ras to Raf
US5645982A (en) * 1993-08-19 1997-07-08 Systemix, Inc. Method for screening potential therapeutically effective antiviral agents
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease

Also Published As

Publication number Publication date
KR100547929B1 (ko) 2006-02-02
CA2305370A1 (en) 1999-04-08
HK1032206A1 (en) 2001-07-13
JP2001517699A (ja) 2001-10-09
US6093728A (en) 2000-07-25
CA2305370C (en) 2006-11-28
NZ503432A (en) 2002-11-26
PL339744A1 (en) 2001-01-02
ES2230719T3 (es) 2005-05-01
SK4152000A3 (en) 2002-02-05
ATE281834T1 (de) 2004-11-15
UA72448C2 (en) 2005-03-15
NO325663B1 (no) 2008-07-07
WO1999016438A1 (en) 1999-04-08
HUP0004024A2 (hu) 2001-04-28
DE69827516D1 (de) 2004-12-16
IL158649A0 (en) 2004-05-12
AU748849B2 (en) 2002-06-13
NZ517808A (en) 2003-07-25
IL135109A (en) 2007-07-04
ZA988797B (en) 1999-12-02
CN1278172A (zh) 2000-12-27
EP1017384B1 (en) 2004-11-10
SK285357B6 (sk) 2006-11-03
AU9578198A (en) 1999-04-23
NO20001555L (no) 2000-03-24
BR9812682A (pt) 2000-08-22
DE69827516T2 (de) 2005-12-01
KR20010015623A (ko) 2001-02-26
CN1167420C (zh) 2004-09-22
BG104356A (en) 2000-12-29
BG64784B1 (bg) 2006-04-28
US6855723B2 (en) 2005-02-15
TW581815B (en) 2004-04-01
EP1017384A1 (en) 2000-07-12
AR017266A1 (es) 2001-09-05
DK1017384T3 (da) 2005-01-31
RU2230553C2 (ru) 2004-06-20
PT1017384E (pt) 2005-03-31
HUP0004024A3 (en) 2001-10-29
PL191618B1 (pl) 2006-06-30
US20030181480A1 (en) 2003-09-25
IL135109A0 (en) 2001-05-20
IL158649A (en) 2006-12-10
TR200001546T2 (tr) 2000-10-23

Similar Documents

Publication Publication Date Title
NO20001555D0 (no) Azabenzimidazolbaserte forbindelser for modulering av serin/treonin proteinkinasefunksjon
MXPA03011007A (es) Metodos para modular la funcion de serina/treonona proteina cinasa por compuestos basados en 5-azaquinoxalina.
WO2002096867A3 (en) Inhibitors of protein kinase for the treatment of disease
EA200200473A1 (ru) Ингибиторы тирозинкиназы
TR200003514T2 (tr) Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
DE60141347D1 (de) Zusammensetzungen zur beseitigung von unangenehmen gerüchen
DE69918422D1 (de) Phthalazinone pde iii/iv hemmer
DE60227492D1 (de) Hemmstoffe der akt aktivität
NO20013444D0 (no) Triazolforbindelser med dopamin-D3-reseptor-affinet
BR9814374B1 (pt) "urÉias heterocÍclicas substituÍdas e composiÇÕes compreendendo as mesmas"
ATE324877T1 (de) Behandlung von metastatischer krankheit
DE602004026047D1 (de) Hemmer der akt aktivität
TR200402157T2 (tr) Heteroaril süksinamidler ve metalloproteinaz inhibitörü olarak kullanımları
ATE26835T1 (de) Tris(piperidylaminotriazylamino) verbindungen, ihre herstellung und ihre verwendung als stabilisierungsmittel fuer polymere.
EA200100139A1 (ru) Фармацевтические композиции, содержащие 2-хинолоны
BR0209149A (pt) Ftalazinonas
EA200400680A1 (ru) Производные хиназолина для лечения аномального роста клеток
MXPA01006742A (es) Compuestos 3-heteroarilidenil-2-indolinona para modular la actividad de la quinasa de proteina y para utilizarse en la quimioterapia de cancer.
DE69435038D1 (de) Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie
ATE220679T1 (de) Porphyrine und ihre verwendung als photosensitizer
BR0016547A (pt) Composição para a modulação e inibição da permeabilidade vascular (vp)
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
ATE228980T1 (de) Verwendung von alkoholen als additive für putze und/oder mörtel
DE69804125D1 (de) Verwendung von immunomodulatoren
DK162839C (da) N,3-diacyl-2-oxindol-1-carboxamid-forbindelser og 3-acyl-2-oxindol-forbindelser til anvendelse som mellemprodukter ved deres fremstilling